Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic corticosteroids for hepatic ischemia-reperfusion injury after hepatic inflow occlusion
ChiCTR1900021547Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic ischemia-reperfusion injury (HIRI) comparing Hydrocortisone group, Methylprednisolone group and Placebo group (3 arms). Primary endpoints: Inflammatory factors and Liver function. Started Dec 2017; status: recruiting.
02
Drugs
hydrocortisonemethylprednisolone
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)
Beyond the preview
Go deeper on ChiCTR1900021547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021547.